Seeing Red: Clinical Assessment Tools for Clinical Trial Decision Support

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2024

Conditions
Incontinence-associated DermatitisMoisture Associated Skin DamageIntertrigo
Interventions
OTHER

Screening

Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.

All Listed Sponsors
lead

Scotiaderm

OTHER

NCT05760469 - Seeing Red: Clinical Assessment Tools for Clinical Trial Decision Support | Biotech Hunter | Biotech Hunter